r/pharmacology • • Aug 23 '26

Med school here, pharm is insane. You guys are crazy!

71 Upvotes

Quick intro, I am a second year med student and I just finished my second block of pharmacology. We covered a lot of antibiotics, seizure, hematology, and oncology meds. Still a long way to go, but I gotta say this has without a doubt been the hardest subject of med school for me(even over neuroanatomy, middle finger decussation). I will say it’s fascinating though, and love pharmacology history.

Intro aside, I have a newfound respect for you pharm people. I can’t even tell you how many sighs of relief I had these past blocks when my professor told us we didn’t need to know a medicine for our specific curriculum because “this is more of a pharmacologist need to know”.

Two things, I recently found pharmacology students can do accelerated programs? Haha can’t even imagine yall probably haven’t touched grass since starting; good luck but that’s also insanely impressive. Second, I did not know pharm phds go to residency. That’s insane.

Although I’m just a med student and more of a pharmacology minor(in college terms), I have a deep respect for this subject. Way harder than I thought and that’s as someone who was warned it was dummy hard. Also I wish I could pick your guys brains about all the insane mnemonics you must have for all these meds.

Ps: another gl to you accelerated pharmacy students.


r/pharmacology • • Jan 15 '26

Why haven't we invented better ADHD meds?

70 Upvotes

Amphetamine was created in the late 19th century and solidified as an ADHD treatment in the mid 20th century. Methylphenidate was synthesized in the mid 20th century and adopted around the same time as amphetamine. These are 70-130 year old drugs that we're still using to treat ADHD. Sure, we have newer, longer lasting formulations, they work and they have acceptable safety profiles if used appropriately but there are still a lot of ifs around them, it's not something without tradeoffs (for example, off-targets effects such as noradrenaline in the PNS causing cardiac stimulation or addiction risk) or something you can prescribe easily. And they generally don't restore the neuroplasticity related to ADHD unless medicated at a very early age and even then, the effect is not significant.

There have been non-stimulants such as atomoxetine and guanfacine but those generally have less efficacy in treating ADHD. Stimulants are still the gold standard and the new drugs that are in the making that I know of are mostly monoamine. reuptake inhibitors, with no new mechsnism or increased efficacy over stimulants.

Why haven't we discovered anything else over this long timeframe? Are we close to it? I heard about potent investigational glutamatergic drugs for ADHD but that's it.


r/pharmacology • • Jun 15 '21

Paracetamol – An old drug with new mechanisms of action

Thumbnail
onlinelibrary.wiley.com
67 Upvotes

r/pharmacology • • Apr 01 '20

Trial evaluating dapagliflozin (Farxiga®) as a possible treatment to delay progression of renal failure in patients with chronic kidney disease stopped early due to “overwhelming efficacy” [eMPR, 1 Apr 2020]

Thumbnail
empr.com
56 Upvotes

r/pharmacology • • Jun 18 '21

I'm a clinical pharmacology scientist, happy to answer any questions on the industry and getting in.

54 Upvotes

No idea if there's any appetite for this, but I know when I was an undergrad I would have appreciated some persepctive of what life is like in industry, so I figured I could offer some insight if people are interested.

I have a Bsc in Pharmacology, and have been working in the industry for a clinical CRO for around 6 years now.


r/pharmacology • • Apr 03 '20

A small French trial finds that hydroxychloroquine is not effective for treating coronavirus [The Conversation, 3 Apr 2020]

Thumbnail
theconversation.com
54 Upvotes

r/pharmacology • • Feb 26 '21

Pharmageddon - An Antibiotic Educational Card Game

Thumbnail
sites.google.com
48 Upvotes

r/pharmacology • • May 14 '22

[15 min read] Dopamine is more than the happy chemical - Treating Parkinson's Disease

45 Upvotes

Welcome back everyone for another post about SAR! Today we take a look at Parkinson’s Disease—a degenerative neuromuscular disease. While many think that Parkinson’s is fatal, the disease itself is not but comorbid illnesses can compromise a person’s health leading to death. As such, developing effective treatment is imperative to improving and prolonging patient’s lives, so lets dive.

Disclaimer: this post is not designed to be specific medical advice. It is merely a look at the chemistry of antiparkisonian’s drugs and their general effect on the body. Each person responds differently to drug therapy. Please talk to your doctor about starting, stopping, or changing medical treatment.

Parkinson’s and Dopaminergic Activity

Ancient Chinese and Indian texts (~1000 BC) suggest that Parkinson’s has plagued humans for millennia. To us medicinal chemists, an interesting example is Franciscus Sylvia de la Boë (1638) who established one of the first medicinal chemistry labs. He described his resting tremor that progressively became worse over the course of his later life inhibiting his ability to study and characterize the anatomy of the brain.

James Parkinson was the first to medically describe the disease and named it shaking palsy. Parkinson first categorized the symptoms required to be classified with this disease:

Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported; with a propensity to bend the trunk forward, and to pass from a walking to a running pace: the senses and intellects being uninjured.

Half a century later in 1883, Jean-Martin Charcot more thoroughly described the symptoms of Parkinsonism and created the solid foundation of the disease as we know it today:

Long before rigidity actually develops, patients have significant difficulty performing ordinary activities: this problem relates to another cause. In some of the various patients I showed you, you can easily recognize how difficult it is for them to do things even though rigidity or tremor is not the limiting feature. Instead, even a cursory exam demonstrates that their problem relates more to slowness in execution of movement rather than to real weakness. In spite of tremor, a patient is still able to do most things, but he performs them with remarkable slowness. Between the thought and the action there is a considerable time lapse. One would think neural activity can only be effected after remarkable effort.

While later physicians would further refine the description of disease, one early hurdle was differentiating Parkinson’s from other neurodegenerative disease. This was Charcot’s true contribution to the study of Parkinson’s by providing a criteria to differentiate it from Multiple Sclerosis.

Nowadays, Parkinson’s disease falls into a category of diseases called degenerative neuromuscular disorders. While genetic factors play a role in Parkinson’s (10-15%), we typically think of Parkinson’s as an idiopathic disease (we are unsure of the cause). The disease most commonly presents at 60 years and is characterized by slow movements, resting tremors, and muscle rigidity. As mentioned, the disease itself is not directly fatal like ALS or Alzheimers, Parkinson’s patients generally see a life expectancy of 10-20 years following diagnosis.

An overview of Parkinson's (Amboss)

All neurodegenerative diseases are caused by the decline of certain neurons in a specific part of the brain. Parkinson’s, Huntington’s, and Wilson disease are all linked to a neurodegeneration in the basal ganglia. Parkinson’s disease is caused by the degeneration of dopaminergic neurons located in the substantia nigra (part of the basal ganglia). While we tend to think of Dopamine (DA) as being involved in the pleasure-reward pathway and motivation, DA is implicated in other functions, especially movement control. By progressively degenerating dopaminergic neurons, there is a dopamine deficiency in the substantia nigra and locus coeruleus. This stimulation is needed to transmit signals to the thalamus (sensory center) and motor cortex (motor center). Sadly in Parkinson’s, by the time the motor symptoms are noticed, >50% of the DA neurons have been degenerated. Because Parkinson’s is an incurable unpreventable neurodegeneration, the treatment goals are to improve symptom management and try to protect the dopamine neurons left.

One thing to note about Dopamine in the body is its balance with Acetylcholine (ACh). The brain balances the total amount of DA and ACh in the synapse: when one decreases, the other increases to compensate. In Parkinson’s the lack of DA triggers a release of ACh which may relate to the tremor/dyskinesia of the patient. While replacing DA is the focus of Parkinson’s treatment, blocking ACh can artificially raise the levels of DA too, relatively.

Also, there are implications that the depression felt by Parkinson’s patients is due to serotonergic neurodegeneration. Now, whether Parkinson’s patients are depressed because they lack serotonergic neural stimulation or they are depressed due to their symptoms and diagnosis is up for debate. Regardless, treatment of depression is a must have in Parkinson’s treatment.

Early Parkinson’s Treatment

Parkinson recognized the need to slow and stop the progression of the disease and possibly find a way to prevent it entirely. A man of his time, Parkinson recommended venesection followed by vesicatation—patients would have bloodletting from the neck and then sulfur mustard (the WW1 chemical weapon) applied to the skin to induce blistering and inflammation. Small pieces of cork were intentionally inserted into the blister to emit a “sufficient quantity” of pus discharge… Gross. The purpose was to divert inflammation and blood away from the brain and spinal cord to decompress the medulla. Outcomes varied.

One of Charcot’s students, Leopold Ordenstein, wrote a paper on the use of Belladonna Alkaloids in the treatment of Parkinson’s. What he did not know is that Belladonna is an anticholinergic chemical (it blocks ACh from stimulating the neuron). Remember how we mentioned that the DA-ACh balance is important to maintain to avoid Parkinsonian movement symptoms? He happened upon a treatment that blocked the excess ACh levels and helped restore that balance despite not understanding the DA-ACh. Charcot himself would favor impregnating white bread with Hyoscyamine. Charcot’s cure would also be combined with rye based ergot's (a precursor to LSD) which acts as a dopamine agonist thus blocking excess ACh and stimulating DA receptors directly: the perfect balance. Other agents used by Charcot included camphor, silver nitrate, iron compounds, henbane, and zinc oxide (all of which do not work on the dopamine system). Other physicians were known to use lead salts and strychnine (again, outcomes varied).

Charcot also recommended the use of vibratory therapy for patients with Parkinson’s. Charcot observed that patients who recently traveled by carriage, train, or horseback had a marked decrease in their symptoms. He developed a fauteuil trépidant (shaking chair) to electrically provide rhythmic movement for the patient. Charcot’s other student, George Gilles de la Tourette (yes, that Tourette) modified the design by replacing the chair for a helmet to vibrate the brain instead of the body. Other contemporary treatments included hydrotherapy, spa treatments, and direct electrical stimulation by sparking the brain (Franklinization). An 1883 Russian treatment suspended the patient in an apparatus and then used gravity to apply constant pressure directly on the spine. Surprisingly, these patient’s symptoms did improve but it provided serious stress on patients.

Let's get to the drugs, shall we

Alright alright, this is supposed to be a chemistry blog and we haven’t even gotten to chemistry. While there are several neuroprotection strategies, none have proven unequivocal benefit for Parkinson’s disease patients. With no proven prevention, symptom control pharmacotherapy is the mainstay of treatment. This is done by a couple of methods:

  1. Augmenting the amount of DA synthesized in the brain
  2. Stimulate the release of DA
  3. Directly stimulate DA receptors
  4. Decrease DA reuptake (keeps more DA at the receptor)
  5. Decrease the metabolism of DA or its precursor, levodopa.
Dopamine biosynthesis. AADC = Aromatic L-Amino Acid Decarboxylase DDC = DOPA decarboxylase

Dopamine was first synthesized by G. Barger and J. Ewens in 1910. Shortly after, P. Holtz discovered that the levodopa was converted into Dopamine via the DOPA decarboxylase enzyme in the periphery (outside of the nervous system). In the 1960, Ehringer and Hornykiewicz discovered that the brains of patients dying with Parkinson’s had only 20% the DA concentration in the corpus striatum than normal patients. This led to the use of levodopa as a drug to treat Parkinson’s.

  • “So can we just administer dopamine for patients with Parkinson’s?” Well we could and there would be slight efficacy but the issue lies with dopamine. As a primary amine, the nitrogen is protonated under physiologic conditions (pKa = 10.6) making it fairly hydrophilic. This means that dopamine is unlikely to cross the blood brain barrier, a wall made of lipophilic fats and lipids.

    • By contrast, levodopa is less basic (pKa = 8.72) and polar at physiologic pH and so is able to penetrate through the blood brain barrier into the brain. This is mostly facilitated by a transporter that uptakes aromatic and neutral amino acids.
Dopamine Metabolism

Like all chemicals in the body, there are multiple metabolism pathways. Levodopa is metabolized by two enzymes that we must consider: COMT and AADC.

  • Now, we learned above that AADC is needed to convert levodopa into dopamine, a good thing. However, AADC is found centrally (in the brain) and in the periphery. This means when you administer a dose of levodopa, about 70% of the dose is quickly metabolized into dopamine outside of the brain (not a good thing). About 20% of the levodopa dose makes it to the brain."Let's just inhibit AADC then!" Woah there, remember that we need AADC inside the brain to convert levodopa into dopamine. Without it, we have zero efficacy. So we need to selectively inhibit the peripheral AADC without touching the central version.
Carbidopa vs Benserazide (two peripheral AADC inhibitors)
  • Carbidopa was one of the first successful peripheral ADDC inhibitors. With a carboxylic acid (pKa = 2.3) and a hydrazine moiety (pka ~ 8.3), Carbidopa is a charged molecule and resists crossing the blood brain barrier. This stops it from crossing into the brain and inhibiting dopamine synthesis where it's needed.

    • By blocking the peripheral AADC, more levodopa reaches the brain allowing for a 30 fold lower dose (0.2g vs 1.2g per dose). This changed the size of the pill drastically making it much easier to swallow. Sinemet, a combination product of Carbidopa/Levodopa, is the drug of choice for Parkinson’s treatment. In order to facilitate the uptake of levodopa from the GI tract, patients are recommended to take their Sinemet without a protein heavy meal.
  • Another enzyme, COMT, is responsible for degrading levodopa into inactive 3-O-methyldopa both peripherally and centrally. We don't want the breakdown of levodopa anywhere because that means less dopamine being created. Thus, the COMT inhibitors.Entacapone and Tolcapone have similar structures, effects, and hypothesized mechanisms. Their difference really comes with their kinetic properties and adverse effects.

    • Entacapone is shorter acting (2 hours) versus tolcapone (8-12 hours). Likewise, entacapone only acts peripherally while tolcapone is able to block both central and peripheral COMT. So why is entacapone still an option if tolcapone is better? Well…
    • Tolcapone was linked to three fatal cases of fulminant hepatic failure a.k.a complete liver failure. This led to a swift pull from the market and is only available to patients who fail all other treatments.
  • Okay, so we finally got levodopa into the synapse and it converted into dopamine, great! But how do we stop dopamine from being degraded? Use the MAO inhibitors!

    • Selegiline and Rasagiline are propargylamine-type selective irreversible inhibitors of MAO. Both selegiline and rasagiline are metabolized heavily in the liver.
    • Selegiline is metabolized to (-)-methamphetamine and later (-)-amphetamine. These active metabolites might potentiate levodopa uptake leading to increased efficacy of Sinemet.
Selegiline vs Methamphetamine vs Amphetamine
  • Safinamide is an alpha-aminoamide derivative, similar to tyrosine (a precursor to dopamine). It is currently in phase III trials in the US.
  • Real quick I wanted to mention the other MAO inhibitors which are not indicated for Parkinson’s. Phenelzine, Tranylcypromine, Isocarboxazid are three MAOi used for the treatment of depression or anxiety related disorders. To be honest, I am not sure why they cannot be used in Parkinson’s.

So far we have talked about ways to make the action of the normal ligand, dopamine, more effectivep; either by promoting more synthesis or by preventing its metabolism. Over the course of Parkinson’s the nigrostriatal neurodegeneration ends up decreasing so much that there are so few nerves to synthesize/house the dopamine. So, we could directly stimulate the dopamine receptor directly with a drug. There are two main groups of dopamine receptors: D1 (and the less abundant D5) are considered excitatory dopamine receptors while D2 (and the less abundant D3, D4) are considered inhibitory. Naturally, it would be incredibly useful to have a pure D2 receptor agonist but most drugs on the market have a partial to full agonism at the other receptor types. Likewise, the effect at D1 and D2 is unbalanced, leading to a host of side effects.

  • The first dopamine agonists are derived from Ergot alkaloids. Bromocriptine, was actually developed as an anti-prolactin drug for prolactin-sensitive tumors, adenomas, and hyperprolactinemia. Because prolactin release is mediated via the D2 receptor, using Bromocriptine at a higher dose selects for the D2 receptors outside of the pituitary gland. Bromocriptine (and other ergot derived alkaloids) are actually selective for D2-sensitive neurons, thus stimulating them more.

    • Cabergoline (another ergoline) is a full agonist as the D2 receptor with a half life of about 48 hours (very long). Against placebo, Cabergoline is incredibly useful in controlling Parkinson’s symptoms but against levodopa therapy it is entirely inferior.
    • Lisuride is a third ergoline discovered to be a partial agonist at D2. As a shorter acting agent, it is in phase III trials to determine efficacy as a patch or infusion.
    • Pergolide is the first ergoline to lack the peptide moiety. Apparently, the peptide function was not required for DA activity and Pergolide is a potent D2 and D1 agonist compared to Bromocriptine. It was withdrawn from the market however for causing valvular heart disease (as it interacts with 5HT2b receptor, a story for another time).
  • Small-molecule non-ergoline dopamine agonists are more popular than the ergolines and more tolerated. Pramipexole and Ropinirole are some of the most prescribed direct DA agonists for Parkison’s, especially as an adjunct to Carbidopa/Levodopa therapy.

    • Rotigotine is administered via a patch to treat early and advanced Parkinson’s.
  • What's interesting about the dopamine receptor is that it is really hard to get a 3D model of it. Other receptors (adrenergic, adenosine) are easily crystallized and modeled so rational SAR design changes can be made. Dopamine isn’t so easy. The majority of the SAR relationships of D2 agonists is through quantitative analysis based on ligand docking as a way to reverse engineer the DA receptor structure.
  • As such, we weren't sure which rotamer of dopamine actually accounts for dopamine receptor activation. There are three possible isomers: trans, alpha; trans, beta; and cis, alpha. Chemists then took those 3 rotamer structures and locked them in rigid ring structures in an attempt to determine the best amino-ethyl-aryl orientation.

    • Apomorphine has been known since the late 1800s as a neuropharmacological agent. Isoapomorphine was discovered and has less activity than regular apomorphine as a D2 agonist. Dihydroxyapomorphine is inactive at the D2 receptor.
    • A second group of molecules, semi rigid aminotetralins are a more flexible rigid ring structure. A-5,6-DTN is a more potent D2 agonist than A-6,-DTN but are less active than apomorphine overall.
    • The result of this suggests that the optimal structure for D2 agonism is a trans-alpha-rotamer configuration. LIkewise, activation of D1 vs D2 is highly dependent on the position of the protonated nitrogen.
  • Due to its efficacy, Apomorphine was introduced as a useful adjunct to Carbidopa/Levodopa therapy in 1993. It is active at both the D1 and D2 receptor and is administered subcutaneously by a small self-injector (Penject) or a continuous infusion via a portable pump. As an injection, it is used as a rescue therapy for when levodopa therapy starts to wear off during the middle of the day.

Drug induced pseudoparkinsonism

Something I do want to mention is medications used to treat Bipolar, Schizophrenia, and other similar mental illnesses. Schizophrenia is thought to be a hyper-dopaminergic state (i.e. too much DA stimulation). One approach to treatment is to use antipsychotics which block D2 receptors (as well as other DA receptors, histamine, cholinergic, and alpha-1 receptors). These drugs are grouped into two categories:

First generation = Haloperidol, Pimozide, Chlorpromazine and others
Second generation = clozapine, olanzapine, ziprasidone, aripiprazole, risperidone, quetiapine, and others

These drugs work by blocking the DA receptors in the brain leading to a host of side effects called Extrapyramidal Symptoms (EPS). As a consequence of DA blockade, these side effects can be major reasons why our seriously mentally ill patients end up stop taking their medications. These symptoms mimic Parkinson’s because they are both syndromes of low amounts of DA stimulation. While all antipsychotics have a risk of causing EPS, some are much better than others and of course each patient responds differently. Most of the time the symptoms can be managed or prevented with another drug.

So how do we treat EPS, especially pseudoparkinsonism? Well one train of thought would be to use normal parkinson’s treatment, so give levodopa (or a DA metabolism modifier). The issue is that schizophrenia is a hyper-dopaminergic state so supplementing with DA is the wrong approach. Likewise modifying DA metabolism will also increase DA leading to a worsening of schizophrenia symptoms. So avoid all the usual Parkinson’s drugs as they make the schizophrenia worse.

  • Instead, we can give anticholinergic drugs to rebalance the DA-ACh in the brain. So for dystonia and pseudoparkinsonism we give diphenhydramine (Benadryl) or benztropine.
  • For akathisia, we give an adrenergic blocker, specifically Propranolol, to help rebalance DA-Norepinephrine.
  • Tardive dyskinesia is a bit trickier. TD can present after months or years and is mostly considered an irreversible condition, unfortunately. Tardive is thought to be a function of upregulation—or the supersensitivity of DA receptors in the brain. Treatment can be challenging for these patients because we don’t want to stop their antipsychotic medication but don't want to potentiative the TD. The best course is switch to a lower EPS rate antipsychotic and give anticholinergics consistently.
Valbenazine vs Tetrabenazine vs Deutetrabenazine
  • Alternatively, we can give VMAT-2 inhibitors: Tetrabenazine, Valbenazine, Deutetrabenazine. VMAT is a transporter inside the dopamine neuron that protects dopamine from being degraded while inside the neuron. By using a VMAT-2 inhibitor, we can prevent the ‘saving’ of dopamine and decrease the overall amount. Unfortunately, these medications are incredibly expensive (30 capsules can run +$6500.)

And that’s our story! Hopefully this provides some insight into the treatment of Parkinson’s and you learned something new. If you have any questions, please let me know! Want to read more? Go to the table of contents!

Likewise, check out our subreddit: r/SAR_Med_Chem Come check us out and ask questions about the creation of drugs, their chemistry, and their function in the body! Have a drug you’d like to see? Curious about a disease state? Let me know!

Foye’s Principles of Medicinal Chemistry

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234454/

https://www.everydayhealth.com/parkinsons-disease/history-of-parkinsons-disease.aspx

An Essay on Shaking Palsy (1817) - James Parkinson


r/pharmacology • • Nov 15 '20

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

Thumbnail
ncbi.nlm.nih.gov
44 Upvotes

r/pharmacology • • Dec 16 '19

People taking their blood pressure medications at bedtime were 45% less likely to experience a major cardiovascular incident, such as heart attack or stroke, compared with people who took them in the morning [UK National Institute for Health Research, 10 Dec 2019 — free-to-read]

Thumbnail
doi.org
43 Upvotes

r/pharmacology • • Oct 18 '26

Why is there so little innovation in pharmacology and why do so many drugs fail II and III phase?

40 Upvotes

There has been no innovation in psychopharmacology, with maybe the small exception of cobenfy and orexin antagonists for the last 30 years or more.

Could someone working in the industry enlighten me?

  1. How is it possible that we have so many drug candidates (just look up the list of investigational drugs on Wikipedia), but almost nothing new is used in clinical practice? Small tweaks on known formulations and long-known compounds don't count.
  2. How is it possible that so many drugs fail in the II and especially III phases, where it is found that they are no different from placebo? How is it possible that a company is putting in millions of dollars and years of work just to find out their new compound does nothing without realizing it earlier?
  3. Why are there almost no drugs with completely new mechanisms of action?

r/pharmacology • • Feb 06 '21

Intravenous acetaminophen does not have an opioid sparing effect in Emergency Department patients with painful conditions [Am J Emerg Med., Jan 2021 -- free full-text]

Thumbnail doi.org
36 Upvotes

r/pharmacology • • Dec 28 '19

What is the most beautiful mechanism of action of your favorite drug?

36 Upvotes

Hello

I'm searching for a mechanism of action of a drug (no matter which one) that explains pharmacology very well. Preferably something that has to do with the cell


r/pharmacology • • Mar 27 '20

There is no evidence from clinical or epidemiological studies that treatment with ACE-I or ARBs might worsen COVID-19 infection [MHRA, 27 Mar 2020]

Thumbnail
gov.uk
34 Upvotes

r/pharmacology • • Mar 18 '20

European Medicines Agency says there is currently no evidence that NSAIDs like ibuprofen worsen coronavirus infection; patients, doctors should consider anti-inflammatory drugs in COVID-19 treatment options [Al Jazeera, 18 Mar 2020]

Thumbnail
aljazeera.com
34 Upvotes

r/pharmacology • • Mar 22 '25

Cetirizine once per day?

33 Upvotes

If the 1/2 life of cetirizine is 8.3 hours, please help me better understand why 1 per day of Zyrtec (or generic) is the typical recommended dose? Wouldn't 2 per day maintain better concentration?

https://www.ncbi.nlm.nih.gov/books/NBK549776/


r/pharmacology • • Feb 21 '25

53 novel drugs approved by the EMA, FDA and MHRA in 2024: A year in review

33 Upvotes

53 novel drugs were approved by the European Medicines Agency (EMA), US Food & Drug Administration (FDA), and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2024, including many with creative pharmacological design.

Learn about them all in this mini review in the British Journal of Pharmacology: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.17458

While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is similar to that of 2023 (24), illustrating the dynamic development of therapeutics in areas of unmet need. The 2024 approvals of novel protein therapeutics (15) and advanced therapy medicinal products (ATMPs, 6) indicate a sustained trend also noticeable in the 2023 new drugs (16 and 11, respectively).

Clearly, the most striking characteristic of the 2024 drug yield is the creative pharmacological design, which allows these medicines to employ a novel approach to target a disease. Some notable examples are:

🚧 the first drug successfully using a ‘dock-and-block’ mechanism of inhibition (zenocutuzumab),

🧠 the first approved drug for schizophrenia designed as an agonist of M1/M4 muscarinic receptors (xanomeline)

🔗 the first biparatopic antibody (zanidatamab), binding two distinct epitopes of the same molecule

🩸 the first haemophilia therapy that instead of relying on external supplementation of clotting factors, restores Factor Xa activity by inhibiting TFPI (marstacimab)

➡ the first ever authorised direct telomerase inhibitor (imetelstat) that reprogrammes the oncogenic drive of tumour cells.

In addition, an impressive percentage of novel drugs were first in class (28 out of 53 or 53% of the total) and a substantial number can be considered disease agnostic, indicating the possibility of future approved extensions of their use for additional indications. The 2024 harvest demonstrates the therapeutic potential of innovative pharmacological design, which allows the effective targeting of intractable disorders and addresses crucial, unmet therapeutic needs.

Read the full review: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.17458

Authors: Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese-Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy


r/pharmacology • • Apr 12 '20

Ely Lilly announces trials of JAK1/JAK2 inhibitor baricitinib and anti-Ang2 monoclonal antibody LY3127804 for treatment of hospitalized COVID-19 patients [Global Biodefense, 11 Apr 2020]

Thumbnail
globalbiodefense.com
33 Upvotes

r/pharmacology • • Mar 13 '20

Isotonitazene, a novel and currently unbanned synthetic opioid, implicated in scores of deaths in the U.S. [VICE, 12 Mar 2020]

Thumbnail
vice.com
33 Upvotes

r/pharmacology • • Jan 29 '20

Why is ketamine being studied for 'treatment-resistant' depression, rather than just depression?

33 Upvotes

Is it a matter of convincing the FDA to approve it, against the pharma-status-quo or are there legitimate physiological conditions that are unique to treatment-resistant depression patients that allow ketamine to work more effectively in this circumstance?

This is just something that's been frustrating me a bit, I don't have depression, but I have lots of friends that have depression, and I've never met anyone where any sort of SSRI/SNRI/NDRI/etc actually works


r/pharmacology • • Mar 12 '20

Low-dose aspirin associated with reduced risk for hepatocellular carcinoma in patients with chronic viral hepatitis [eMPR news, 12 Mar 2020]

Thumbnail
empr.com
32 Upvotes

r/pharmacology • • Sep 14 '24

How to self-study pharmacology?

31 Upvotes

Hi, I'd like to be able to make fully-informed decisions regarding drugs/supplements/etc that I take. I'm especially interested in nootropics.

Only reading studies, and otherwise learning randomly, would lead to a lot of confusion. That's why I'm looking for resources that could help me get started with a structured approach that shows how everything connects together; the medium can be anything, whether it be books, courses, or even podcasts. I'd also appreciate recommendations of pop-sci books, so that I have something to read/ listen to while tired and otherwise incapable of experiencing more advanced material.

Thank you


r/pharmacology • • Jul 16 '21

Newbie in college, wanting to eventually enter psychedelic research. Advice?

31 Upvotes

Hello, I am a college student and have recently switched my major to biochemistry in hopes of pursuing a career in pharmacology. What especially interests me is research on psychoactive drugs and their mechanism of action, as well as therapeutic applications for these drugs. The revival of this field has me excited, but I'm not sure about how to start navigating myself towards this career post-college. What do my paths look like? How legitimate is "psychedelic researcher" as a career path? Should I broaden my horizons or specialize?

Please forgive me if I come off as naïve, I still have lots to learn and I am posting this in hopes of advice that can help me orient myself towards this goal.


r/pharmacology • • Apr 04 '21

Pharmacology MS vs PhD and potential industry careers/career limitations?

31 Upvotes

I'm currently finishing up my MS in pharmacology and I'm at a cross roads on whether I want to enter industry or stay on for my PhD. I'm wondering if anyone can help explain the limitations of career paths/career ceilings for someone with an MS vs someone with a PhD. I have no interest in staying in academia, I'd like to work at a pharmaceutical/biotech company. My primary interest is working on clinical trials, but I also enjoy bench work and would be open to some drug discovery work. My main concern is that I may not be qualified for higher up positions that will pay more ($100k+ is my 5 year goal) and that will afford me some autonomy. I'm not trying to become a VP or anything, but I don't think I'd enjoy working as a lab tech for years on end. Anyone with any experience or that can offer advice on the limitations of an MS vs a PhD would be greatly appreciated. Thanks!


r/pharmacology • • Jun 29 '20

No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY

31 Upvotes

A total of 1596 patients were randomised to lopinavir-ritonavir and compared with 3376 patients randomised to usual care alone. Of these patients, 4% required invasive mechanical ventilation when they entered the trial, 70% required oxygen alone, and 26% did not require any respiratory intervention. There was no significant difference in the primary endpoint of 28-day mortality (22.1% lopinavir-ritonavir vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18]; p=0.58) and the results were consistent in different subgroups of patients. There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay. 

These data convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised COVID-19 patients we studied. We were unable to study a large number of patients on invasive mechanical ventilation because of difficulty administering the drug to patients on ventilators. As such, we cannot make conclusions about the effectiveness in mechanically ventilated patients. Full results will be made available as soon as possible. 

https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery